Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 22 Jan 2024
PHARMAC publishes agenda for next month's PTAC meeting
18 January 2024 - Surprise, surprise yet another underwhelming agenda. ...
Posted by Michael Wonder on 22 Jan 2024
NICE issues draft guidance for use of remdesivir and also for tixagevimab-cilgavimab for treatment of COVID-19
18 January 2024 - Draft guidance for public consultation has been published by NICE. ...
Posted by Michael Wonder on 22 Jan 2024
Generic drugs in the US are too cheap to be sustainable, experts say
19 January 2024 - Non-brand-name drugs are one inexpensive part of the healthcare system but they’re driving some manufacturers out of ...
Posted by Michael Wonder on 22 Jan 2024
In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property.
22 January 2024 - In the fall of 2020, Robert Sachs was prescribed a medication to treat prostate cancer that had ...
Posted by Michael Wonder on 22 Jan 2024
EMA publishes agenda for 22-25 January 2024 CHMP meeting
22 January 2024 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 22 Jan 2024
Botannix Pharmaceuticals’ resubmission of Sofdra NDA accepted by FDA
22 January 2024 - Botannix Pharmaceuticals’ resubmission of the new drug application for Sofdra has been accepted by the FDA ...
Posted by Michael Wonder on 22 Jan 2024
Australians save $250 million thanks to Albanese Government cheaper medicines
22 January 2024 - Australians have saved $250 million on cheaper medicines in 2023 thanks to the Albanese Government. ...
Posted by Michael Wonder on 21 Jan 2024
First ever treatment for ultra rare rapid ageing disease progeria receives approval in Japan
20 January 2024 - The Progeria Research Foundation marks significant achievement as Zokinvy (lonafarnib) receives Japanese approval for the treatment ...
Posted by Michael Wonder on 21 Jan 2024
Advanced melanoma treatment to be added to Pharmaceutical Benefits Scheme
21 January 2024 - Treatment for advanced melanoma is set to become cheaper under the Pharmaceutical Benefits Scheme in the ...
Posted by Michael Wonder on 19 Jan 2024
Anti-epileptic drug Fycompa injection formulation approved in Japan
18 January 2024 - Eisai announced today that it has obtained marketing authorisation approval from the Japanese Ministry of Health, ...
Posted by Michael Wonder on 19 Jan 2024
Halozyme announces argenx received approval in Japan for Vyvdura (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with Enhanze for generalised myasthenia gravis
18 January 2024 - Vyvdura provides patients with option for self-administration. ...
Posted by Michael Wonder on 19 Jan 2024
Medicare patients on pricey drugs are saving big this year
15 January 2024 - For the first time, Part D plan patients will hit a ceiling on how much they pay ...
Posted by Michael Wonder on 19 Jan 2024
FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma
19 January 2024 - Today, the FDA approved erdafitinib (Balversa, Janssen Biotech) for adult patients with locally advanced or metastatic ...
Posted by Michael Wonder on 19 Jan 2024
Kyverna Therapeutics granted FDA fast track designation for KYV-101 in the treatment of patients with refractory progressive multiple sclerosis
19 January 2024 - The announcement follows the recent IND clearance for KYV-101 to be used in Kyverna's KYSA-7 Phase 2 ...
Posted by Michael Wonder on 19 Jan 2024
300 people to benefit from new treatment for advanced breast cancer recommended by NICE following price deal
19 January 2024 - Around 300 people are set to benefit following NICE’s recommendation of talazoparib tosylate for treating a type ...